Therapeutics and COVID-19: living guideline – World Health Organization

The WHO Therapeutics and COVID-19: living guideline contains the Organizations most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the Download button) and via an online platform, and is updated regularly as new evidence emerges.

This tenth version of the WHO living guideline now contains 19 recommendations, including two new recommendations regarding fluvoxamine and colchicine. No further updates to the previous existing recommendations were made in this latest version.

Other COVID-19 therapeutics that are currently under consideration by WHO include fluvoxamine, colchicine and anticoagulants. This guideline will be updated if/when sufficient new evidence warrants this.

Guidelines regarding the clinical management of COVID-19 patients are included in a further document, COVID-19 Clinical management: Living guideline, that can be accessed via an online platform and in pdf format (or click PDF in top right corner of online platform).

To view previous (now outdated) versions of this guideline, please see the links below:

This document was updated on 14 July 2022

Read more from the original source:

Therapeutics and COVID-19: living guideline - World Health Organization